ASH 2015 | Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III clinical trial of idelalisib plus bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The study included 416 patients, with 207 patients in the idelalisib plus bendamustine and rituximab arm and 209 in the bendamustine and rituximab plus placebo arm. The patients were treated with bendamustine and rituximab for 6 months, then idelalisib or placebo until progression. The primary endpoint was progression-free survival (PFS), which was 11.1 months for the placebo arm and 23.1 months for the idelalisib arm, representing 67% reduction in the risk of progression or death. The most important secondary endpoint met was that overall survival (OS) improved with idelalisib. Dr Zelenetz also discusses the common side-effects of idelalisib.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.